NEW YORK (GenomeWeb) – By combining whole-genome sequencing and artificial intelligence-based analysis, researchers have reported that they were able to quickly identify clinically actionable mutations within a brain tumor sample.

Researchers from the New York Genome Center, Rockefeller University, and IBM analyzed a glioblastoma sample through panel testing as well as whole-genome sequencing. That sequencing data was then analyzed by a team of bioinformaticians and oncologists at the center as well as by IBM's Watson for Genomics.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

The Associated Press reports that gene-edited food may soon be for sale.

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.